Literature DB >> 10837720

Carrier-mediated or specialized transport of drugs across the blood-brain barrier.

.   

Abstract

In the drug development process, it remains a difficult task to regulate the entry of the drugs. However, recent progress in studies of the transporter-mediated influx and efflux of endogenous and exogenous compounds, including synthetic drugs, across the blood-brain barrier (BBB) is beginning to provide a rational basis for controlling drug distribution to the brain. This paper describes mechanisms established in the last decade for carrier-mediated influx and efflux of drugs and endocytosis of biologically active peptides across the BBB. The transport systems at the BBB described here are the uptake transporters for nutrients, such as amino acids and hexoses, monocarboxylates, amines, carnitine and glutathione and efflux transporters, such as P-glycoprotein and multiple organic anion transporters. Delivery of cationized peptides across the BBB via adsorptive-mediated endocytosis is also described. By utilizing such highly specific transport mechanisms, it should be possible to establish strategies to regulate the entry of candidate drugs, including peptides, into the brain.

Entities:  

Year:  1999        PMID: 10837720     DOI: 10.1016/s0169-409x(98)00084-2

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  25 in total

1.  Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers.

Authors:  Helen H Usansky; Patrick J Sinko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

Review 2.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 4.  Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology.

Authors:  Máiria A Deli; Csongor S Abrahám; Yasufumi Kataoka; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 5.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

6.  Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds.

Authors:  John P Frampton; Michael L Shuler; William Shain; Matthew R Hynd
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2008

Review 7.  Prodrug approaches for CNS delivery.

Authors:  Jarkko Rautio; Krista Laine; Mikko Gynther; Jouko Savolainen
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

Review 8.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

9.  Heparin Attenuates the Expression of TNFalpha-induced Cerebral Endothelial Cell Adhesion Molecule.

Authors:  Jeong Ho Lee; Chul Hoon Kim; Gi Ho Seo; Jinu Lee; Joo Hee Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

Review 10.  Novel treatment strategies for brain tumors and metastases.

Authors:  Salma E El-Habashy; Alaa M Nazief; Chris E Adkins; Ming Ming Wen; Amal H El-Kamel; Ahmed M Hamdan; Amira S Hanafy; Tori O Terrell; Afroz S Mohammad; Paul R Lockman; Mohamed Ismail Nounou
Journal:  Pharm Pat Anal       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.